CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 72 enrolled
Drug / intervention
Fluzone® (intramuscular) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01987349
NCT01987349Phase 4Completed
CompareCT.gov

Protective Mechanisms Against a Pandemic Respiratory Virus: B- Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 1, 2009

Stanford University·interventional·Posted Nov 19, 2013·Updated May 12, 2017

In Brief

A Phase 4 clinical trial evaluating Fluzone® (intramuscular) and FluMist® (intranasal) for Influenza. Completed, enrolled 72 participants across 1 site.

Detailed Summary

This study will compare influenza vaccine responses in monozygotic and dizygotic twins.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 19, 2013
Enrollment StartSep 1, 2009
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.6 years ago

Interventions

Fluzone® (intramuscular)biological

Licensed seasonal trivalent inactivated influenza vaccine (IIV3)

FluMist® (intranasal)biological

Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)